Staar Surgical Shares Slide Following Preliminary 2Q Sales

Dow Jones07-17 06:04

Staar Surgical shares retreated after forecasting second-quarter net sales slight below Wall Street's estimate.

Shares declined 12% to $25.36 in post-market trading on Thursday, after ending the market session up 1.7% at $28.98. The stock is up 26% this year.

The company said after the close it expects net sales of $90 million for the second quarter, just missing the $90.2 million analysts expect, according to FactSet. Staar generated net sales of $44.3 million in the same period a year ago.

Staar said the quarter was led by sequential growth in China, solid growth across Asia-Pacific, and double-digit percentage growth in the Americas.

In EMEA, net sales declined by a low-single-digit percentage, due to continuing turmoil in the Middle East. Excluding the Middle East, EMEA sales grew by double digits, proving strong underlying regional demand. The company also noted that geopolitical and macroeconomic headwinds continued to weigh on parts of EMEA and Asia-Pacific, and cautioned that persistent or broader challenges could affect sales.

Staar plans to report second-quarter results on August 12.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

Staar Surgical shares retreated after forecasting second-quarter net sales. The company said after the close it expects net sales in excess of $90 million for the second quarter. Analysts are expecting sales of $90.2 million for the quarter, according to FactSet "Staar Surgical Shares Slide Following Preliminary 2Q Sales," at 6:04 p.m. ET on July 16, incorrectly said the company was expecting net sales of $90 million for the second quarter.

(END) Dow Jones Newswires

July 17, 2026 09:53 ET (13:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Staar Surgical Shares Slide Following Preliminary 2Q Sales

At the request of the copyright holder, you need to log in to view this content

Comments